Understanding how Factor XI affects blood clotting and bleeding disorders
Biochemistry and Pathophysiology of Factor XI and Contact Activation
This study is looking at a protein called Factor XI to see if it can be a new target for safer blood thinners, which could help people with blood clotting issues manage their condition better and lower their risk of dangerous clots.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-10763803 on NIH RePORTER |
What this research studies
This research investigates the role of Factor XI in blood clotting and its potential as a target for new anticoagulant therapies. It focuses on how Factor XIa, the active form of Factor XI, contributes to thrombin generation and the formation of blood clots. By studying both human populations and animal models, the research aims to develop therapies that inhibit Factor XI, potentially leading to safer blood thinners with fewer side effects compared to existing treatments. Patients may benefit from improved management of clotting disorders and reduced risk of thrombosis.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with clotting disorders such as Hemophilia B or those at risk for thrombosis.
Not a fit: Patients who do not have any clotting disorders or related conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of safer anticoagulant medications that minimize bleeding risks for patients.
How similar studies have performed: Previous research has shown promising results in targeting Factor XI for anticoagulation, indicating potential for success in this approach.
Where this research is happening
Nashville, United States
- Vanderbilt University Medical Center — Nashville, United States (Active)
Researchers
- Principal investigator: Gailani, David — Vanderbilt University Medical Center
- Study coordinator: Gailani, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.